Long-term and quality of survival in patients treated for acute lymphoblastic leukemia during the pediatric age

  • Lara Devilli | devilli.lara@gmail.com Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. https://orcid.org/0000-0002-3285-5412
  • Chiara Garonzi Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Rita Balter Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Elisa Bonetti Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Matteo Chinello Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Ada Zaccaron Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Virginia Vitale Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Massimiliano De Bortoli Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Giulia Caddeo Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Valentina Baretta Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Gloria Tridello Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Simone Cesaro Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Abstract

Long-term survival for acute lymphoblastic leukemia (ALL) in children improved over the last three decades up to 80-90% of affected patients. Consequently, the quality of life of survivors has become increasingly important. This study analyses the clinical features and outcome of 119 children with ALL, focusing on the quality of long-term survival in a subset of 22 patients over 18 years of age. Among this group, the 10-year event-free survival and overall survival were 83.1% (C.I. 74.0-89.2) and 88.4% (C.I. 80.9-93.1), respectively. Treatment related long-term medical complications were reported only in 2 patients (9.1%). Secondary school was completed successfully in 20 of 22 patients (89.9%). The remaining 2 patients were still attending at the time of the analysis. In conclusion, current treatment for ALL is well tolerated and does not compromise significantly the quality of life of survivors.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012;30:1663-1669. doi: 10.1200/JCO.2011.37.8018. DOI: https://doi.org/10.1200/JCO.2011.37.8018

Silverman LB, Stevenson KE, Brien JEO,et al. Long-term results of dana-farber cancer institute all consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 2010;24:320–34. doi:10.1038/leu.2009.253. DOI: https://doi.org/10.1038/leu.2009.253

Rizzari C, Lanvers-kaminsky C, Valsecchi MG,et al. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica 2019;104:1812-1821. doi:10.3324/haematol.2018.206433. DOI: https://doi.org/10.3324/haematol.2018.206433

Conter V; Bartram CR; Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206-14. doi:10.1182/blood-2009-10-248146. DOI: https://doi.org/10.1182/blood-2009-10-248146

V Conter, M Aricò, G Basso, et al. Long-term results of the italian association of pediatric hematology and oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010;24,255–264. doi:10.1038/leu.2009.250. DOI: https://doi.org/10.1038/leu.2009.250

Kunstreich M, Kummer S, Laws H-J, et al. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica 2016;101:1295–305. doi:10.3324/haematol.2016.147595. DOI: https://doi.org/10.3324/haematol.2016.147595

Kawedia JD, Kaste SC, Pei D,et al. Pharmacokinetic , pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011;117:2340–7. doi:10.1182/blood-2010-10-311969. DOI: https://doi.org/10.1182/blood-2010-10-311969

Riitta A. Niinimӓki, Arja H. Harila-Saari, Airi E, et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol 2007;25:1498-1504. doi:10.1200/JCO.2006.06.2539. DOI: https://doi.org/10.1200/JCO.2006.06.2539

Kaste SC, Pei D, Cheng C,et al. Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. J Clin Oncol 2015;33:610-15. doi:10.1200/JCO.2014.57.5480. DOI: https://doi.org/10.1200/JCO.2014.57.5480

Dalen EC Van, Caron HN, Kremer LCM: Prevention of anthracycline-induced cardiotoxicity in children : the evidence. Eur J Cancer 2007;43:1134–1140 doi:10.1016/j.ejca.2007.01.040. DOI: https://doi.org/10.1016/j.ejca.2007.01.040

Zerra P, Cochran TR, Franco VI, Lipshultz SE. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Expert Opin Pharmaco 2013;14:1497-1513. doi:10.1517/14656566.2013.804911. DOI: https://doi.org/10.1517/14656566.2013.804911

Ness KK, Armenian SH, Kadan-lottick N, Gurney JG. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol 2011;4:185–197. doi.org/10.1586/ehm.11.8. DOI: https://doi.org/10.1586/ehm.11.8

Kızılocak H, Okcu F: Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors. Turk J Hematol 2019;36:1-11. doi:10.4274/tjh.galenos.2018.2018.0150. DOI: https://doi.org/10.4274/tjh.galenos.2018.2018.0150

Mostou S, Seidel K, Leisenring WM, et al. Endocrine abnormalities in aging survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2016;34:3240-3247. doi:10.1200/JCO.2016.66.6545. DOI: https://doi.org/10.1200/JCO.2016.66.6545

Viana MB, Oliveira Pinto Vilela MI. Height deficit during and many years after treatment for acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2008;50:509–516. doi.org/10.1002/pbc.21396. DOI: https://doi.org/10.1002/pbc.21396

P. J. Moe, A. Holen, A. Glomstein, et al. Long-term survival and quality of life in patients treated with a national all protocol 15–20 years earlier: IDM/HDM and late effects?, Pediatr Hemat Oncol 1997;14:513-524. doi:10.3109/08880019709030908. DOI: https://doi.org/10.3109/08880019709030908

Peckham VC, Meadows AT, Bartel N, Marrero O. Educational late effects in long-term survivors of childhood acute lymphocytic leukemia. Pediatrics 1988;81:127-133. http://pediatrics.aappublications.org/content/81/1/127

Jahnukainen K, Heikkinen R, Henriksson M,et al. Semen quality and fertility in adult long-term survivors of childhood acute lymphoblastic leukemia. Fertil Steril 2011;96:837–42. doi:10.1016/j.fertnstert.2011.07.1147 DOI: https://doi.org/10.1016/j.fertnstert.2011.07.1147

Krawczuk-Rybak M, Płonowski M, Leszczynska E, et al. The influence of different intensity of treatment on hormonal markers of gonadal function in acute lymphoblastic leukemia survivors. Hematol Oncol 2019;37:609–616. doi.org/10.1002/hon.2681.

Byrne J, Fears TR, Mills JL, et al. Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;42:589–597. doi:10.1002/pbc.20033. DOI: https://doi.org/10.1002/pbc.20033

Published
2021-03-05
Info
Issue
Section
Brief Reports
Keywords:
acute lymphoblastic leukemia, pediatric leukemia, survival
Statistics
  • Abstract views: 493

  • PDF: 110
  • HTML: 0
How to Cite
Devilli, L., Garonzi, C., Balter, R., Bonetti, E., Chinello, M., Zaccaron, A., Vitale, V., De Bortoli, M., Caddeo, G., Baretta, V., Tridello, G., & Cesaro, S. (2021). Long-term and quality of survival in patients treated for acute lymphoblastic leukemia during the pediatric age. Hematology Reports, 13(1). https://doi.org/10.4081/hr.2021.8847